
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
GRI Bio is a clinical-stage biotech company that is making significant strides in the treatment of inflammatory, fibrotic, and autoimmune disorders through its novel drug candidates, GRI-0621 and GRI-0803. The company recently reported positive top-line data for GRI-0621 in a Phase 2a study for IPF, highlighting the drug's potential to bring the immune system back to homeostasis. GRI Bio also has a large market potential in the treatment of lupus with its drug candidate, GRI-0803, and the company's current valuation presents an attractive investment opportunity for its potential to address serious diseases.
Bears say
GRI Bio is a clinical-stage biotech company focused on developing therapies for dysregulated immune response disorders that has recently reported a net loss and no Q1 or Q2 guidance. Despite the potential for treatments in large markets such as Lupus and IPF, the lack of revenue and significant negative earnings make the stock unappealing. Additionally, while recent data for GRI-0621 has been positive, the company's focus on only one product may pose a risk for investors.
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares